Altoida has collaborated with Eisai and Ionian University to begin a five-year Alzheimer’s disease study with its artificial intelligence (AI)-based software device.

The multicentre observational study will evaluate thousands of patients across all phases of the Alzheimer’s disease.

The study will see collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHeLab), Department of Informatics at Ionian University.

BiHELab is a research centre engaged in the application of mathematical modeling and machine learning techniques to neurodegenerative diseases.

By using AI, Altoida’s software device will assess test results to help diagnose neurological diseases such as Alzheimer’s disease in the earliest phases.

Designed to be completed on a smartphone or tablet within 10 minutes, the digital test activities use augmented reality (AR) for the simulation of daily living real-world activities.

To validate its device’s capability to detect early neurocognitive impairments, Altoida will assess its software and digital biomarker data alongside a breadth of clinical data, including imaging, genomics, and other biomarker data.

BiHELab will use analytical methods to efficiently quantify and understand hallmark pathological signatures and gain key insights across the breadth of study data.

Eisai chief ecosystem officer Keisuke Naito said: “Through this collaborative study with Altoida and Ionian University, we look forward to gaining new insights into the Alzheimer’s Disease continuum from various aspects of rich data sets.”

In July this year, Altoida secured breakthrough device designation from the US Food and Drug Administration (FDA) to develop its device to use AI to predict the possibility that an individual aged above 55 years with mild cognitive impairment will convert to Alzheimer’s disease.

The company also received funding from the Bill Gates supported Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator for predictive diagnosis of Alzheimer’s in the preclinical phase.

Altoida CEO Travis Bond said: “By using Altoida’s device alongside traditional neuropsychological tests, imaging procedures (PET and MRI), cerebrospinal (CSF) fluid collection procedures, phenotypic assessments, and genomic assessments, this collaboration has the potential to unlock more about the pathology and the progression of Alzheimer’s than has ever been understood before, and to enable a new gold standard with Precision Neurology.”